Resistance to EGF-R (erbB-1) and VEGF-R modulating agents

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Targeted therapies inhibiting Epidermal Growth Factor Receptor (EGF-R) and Vascular Endothelial Growth Factor (VEGF) show promise in cancer treatment.
• Despite initial efficacy, acquired resistance to these targeted agents remains a significant clinical challenge, limiting long-term patient survival.
• Elucidating resistance mechanisms is crucial for developing next-generation therapies and overcoming treatment limitations.

Purpose of the Study:

• To review and summarize the known molecular mechanisms of resistance to anti-angiogenetic (VEGF/VEGF-R) and EGF-R-targeting therapies.
• To highlight how understanding these resistance pathways can inform the development of novel therapeutic strategies.
• To identify key molecular players and genetic alterations associated with treatment resistance in various cancers.

Main Methods:

• Literature review of pre-clinical and clinical studies on targeted cancer therapy resistance.
• Analysis of identified resistance mechanisms for anti-angiogenetic drugs, including bFGF upregulation and myeloid cell recruitment.
• Examination of resistance mechanisms to EGF-R inhibitors, such as bypass pathway activation and specific mutations (e.g., K-ras).

Main Results:

• Four resistance mechanisms to anti-angiogenetic drugs identified: bFGF upregulation, MMP-9 overexpression, SDF-1alpha increase, and HIF-1alpha-induced myeloid cell recruitment.
• Multiple resistance mechanisms to EGF-R inhibitors documented: alternative tyrosine kinase activation (c-MET, IGF-1R), increased angiogenesis, downstream mediator activation (PTEN, K-ras), and EGF-R mutations.
• K-ras mutations strongly correlate with non-response to EGF-R tyrosine kinase inhibitors in Non-Small Cell Lung Cancer (NSCLC) and colorectal cancer.

Conclusions:

• Identification of specific resistance mechanisms has spurred the development of new targeted therapies.
• Ongoing research continues to uncover additional resistance pathways, offering hope for improved cancer treatment efficacy.
• Translating findings on resistance mechanisms into effective clinical strategies is essential for advancing cancer patient survival.